People with type 2 diabetes die from CVD at rates of 2-4 times higher than populations of similar demographic characteristics without diabetes. They also experience increased rates of nonfatal myocardial infarction and stroke. Since the publication of the DCCT and UKPDS blood glucose lowering data we, diabetes specialists, have been doing just that in order to lower the risk of future complications. I therefore find the reason for the blood glucose lowering arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial being stopped a worry.

The ACCORD trial was launched in the US in 2003 to investigate the best approaches to lowering the risk of heart disease ...